Laboratory Corporation of America Holdings (NYSE:LH) – SunTrust Banks issued their Q3 2017 earnings per share (EPS) estimates for shares of Laboratory Corporation of America Holdings in a research note issued on Monday. SunTrust Banks analyst D. Macdonald anticipates that the medical research company will earn $2.46 per share for the quarter. SunTrust Banks also issued estimates for Laboratory Corporation of America Holdings’ Q4 2017 earnings at $2.45 EPS, FY2017 earnings at $9.60 EPS, Q1 2018 earnings at $2.42 EPS, Q2 2018 earnings at $2.75 EPS, Q3 2018 earnings at $2.69 EPS, Q4 2018 earnings at $2.65 EPS, FY2018 earnings at $10.50 EPS and FY2019 earnings at $11.40 EPS.

Other equities analysts have also recently issued reports about the company. Craig Hallum reiterated a “buy” rating and issued a $179.00 target price (up from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Thursday, July 27th. Credit Suisse Group cut Laboratory Corporation of America Holdings to a “hold” rating and set a $146.00 target price on the stock. in a report on Thursday, July 13th. They noted that the move was a valuation call. Barclays PLC reiterated an “overweight” rating and issued a $182.00 target price (up from $175.00) on shares of Laboratory Corporation of America Holdings in a report on Monday, July 17th. BidaskClub upgraded Laboratory Corporation of America Holdings from a “buy” rating to a “strong-buy” rating in a report on Wednesday, June 28th. Finally, Robert W. Baird reiterated a “hold” rating on shares of Laboratory Corporation of America Holdings in a report on Sunday. Five research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Laboratory Corporation of America Holdings has an average rating of “Buy” and a consensus target price of $164.00.

COPYRIGHT VIOLATION NOTICE: “Laboratory Corporation of America Holdings (LH) Forecasted to Earn Q3 2017 Earnings of $2.46 Per Share” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/20/laboratory-corporation-of-america-holdings-lh-forecasted-to-earn-q3-2017-earnings-of-2-46-per-share.html.

Shares of Laboratory Corporation of America Holdings (NYSE LH) opened at 154.15 on Wednesday. Laboratory Corporation of America Holdings has a 12-month low of $119.51 and a 12-month high of $164.22. The firm has a market capitalization of $15.69 billion, a P/E ratio of 21.59 and a beta of 0.94. The stock has a 50 day moving average of $156.24 and a 200-day moving average of $147.88.

Laboratory Corporation of America Holdings (NYSE:LH) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.47 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.40 by $0.07. Laboratory Corporation of America Holdings had a net margin of 7.57% and a return on equity of 16.85%. The company had revenue of $2.50 billion for the quarter, compared to the consensus estimate of $2.47 billion. During the same period last year, the company earned $2.36 earnings per share. The firm’s revenue was up 4.9% compared to the same quarter last year.

Several institutional investors have recently made changes to their positions in LH. Acrospire Investment Management LLC increased its position in shares of Laboratory Corporation of America Holdings by 16.5% during the 2nd quarter. Acrospire Investment Management LLC now owns 705 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 100 shares during the last quarter. Sun Life Financial INC increased its position in shares of Laboratory Corporation of America Holdings by 9,200.0% during the 2nd quarter. Sun Life Financial INC now owns 744 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 736 shares during the last quarter. Parallel Advisors LLC increased its position in shares of Laboratory Corporation of America Holdings by 377.7% during the 1st quarter. Parallel Advisors LLC now owns 1,261 shares of the medical research company’s stock valued at $177,000 after purchasing an additional 997 shares during the last quarter. IFP Advisors Inc increased its position in shares of Laboratory Corporation of America Holdings by 83.9% during the 2nd quarter. IFP Advisors Inc now owns 1,146 shares of the medical research company’s stock valued at $177,000 after purchasing an additional 523 shares during the last quarter. Finally, Hourglass Capital LLC purchased a new stake in shares of Laboratory Corporation of America Holdings during the 2nd quarter valued at $200,000. 93.19% of the stock is owned by hedge funds and other institutional investors.

In other news, insider Lisa J. Uthgenannt sold 5,000 shares of the firm’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $160.00, for a total transaction of $800,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director R Sanders Williams sold 3,100 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $156.88, for a total value of $486,328.00. Following the sale, the director now directly owns 10,073 shares of the company’s stock, valued at $1,580,252.24. The disclosure for this sale can be found here. Insiders sold a total of 222,968 shares of company stock valued at $34,980,922 over the last three months. 0.90% of the stock is currently owned by insiders.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Earnings History and Estimates for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.